durvalumab + docetaxel

**Durvalumab + docetaxel** is a combination drug therapy used in oncology, specifically as an investigational treatment for various cancers including non-muscle invasive bladder cancer (NMIBC) and gastric cancer. Durvalumab is a human monoclonal antibody targeting PD-L1, blocking its interaction with PD-1 and CD80, thereby promoting immune-mediated tumor cell death (checkpoint inhibition)[1][6]. Docetaxel is a cytotoxic small molecule belonging to the taxane class that stabilizes microtubules and prevents cell division, leading to cancer cell death[6]. This combination is under clinical investigation for its synergistic effect: durvalumab reactivates cytotoxic T cells, while docetaxel induces tumor cytotoxicity, potentially increasing tumor antigen release and enhancing immune-mediated anti-cancer effects. The drugs are administered with durvalumab intravenously and docetaxel either intravenously (standard use) or intravesically in certain NMIBC protocols[1][6]. The combination has shown promising efficacy and safety profiles in early and mid-stage trials.

Other names

durvalumab + docetaxel